Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guo-Ming Shi

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Cancer Medicine|September 20, 2022
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II studyGuo-Ming Shi, Xiao-Yong Huang, Tian-Fu Wen, et al.
Nature Communications|January 20, 2024
Macro CD5L<sup>+</sup> deteriorates CD8<sup>+</sup>T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinomaJia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, et al.
The New England Journal of Medicine|March 4, 2026
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic CholangiocarcinomaGuo-Ming Shi, Xiao-Yong Huang, Fei Liang, et al.
Journal of Clinical and Translational Hepatology|January 1, 2024
Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)Han Wang, Jun Chen, Xin Zhang, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Cancer Medicine|September 20, 2022
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II studyGuo-Ming Shi, Xiao-Yong Huang, Tian-Fu Wen, et al.
Nature Communications|January 20, 2024
Macro CD5L<sup>+</sup> deteriorates CD8<sup>+</sup>T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinomaJia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, et al.
The New England Journal of Medicine|March 4, 2026
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic CholangiocarcinomaGuo-Ming Shi, Xiao-Yong Huang, Fei Liang, et al.
Journal of Clinical and Translational Hepatology|January 1, 2024
Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)Han Wang, Jun Chen, Xin Zhang, et al.
Pageof 10